Brain Tumor Drugs Industry Forecast 2025-2034: Market Expansion, Trends, and Competitive Landscape

 

The brain tumor drugs market size has grown strongly in recent years. It will grow from $3.81 billion in 2024 to $4.09 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%.  The growth in the historic period can be attributed to the increasing prevalence of neurological disorders, increased healthcare expenditure, increased number of approvals for oncology (cancer) drugs, increase in pharmaceutical R&D expenditure, and advances in cancer drug discovery.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%.  The growth in the forecast period can be attributed to an increase in cancer incidence rate, rise in healthcare expenditure, increasing geriatric population, strong pipeline of drugs, and revised FDA regulations to facilitate biologics drug development. Major trends in the forecast period include investing in a combination of drugs for brain tumor treatment, adapting the use of phase zero clinical trials to improve efficacy, use of technology for drug delivery that improves the efficacy of the drug, focusing on the expansion of cell and gene therapy, and carrying out strategic mergers and acquisitions.

Get Your Free Sample of The Global Brain Tumor Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2588&type=smp

What are the key drivers behind the rapid expansion of the brain tumor drugs market?
The major driving factor responsible for the growth of the Brain Tumor drugs market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections, and sedentary lifestyles. For example, as per the National Brain Tumor Society, around 700,000 people in the United States around 700,00 people are having a primary brain tumor, and around 86,000 more will be diagnosed. The increasing number of patients with neurological disorders including brain tumors is leading to a rise in the demand for growth of the brain tumor drugs market drugs used in their treatment.

What is the segmentation for the brain tumor drugs market?
The brain tumor drugs market covered in this report is segmented –
1) By Drugs: Temozolomide, Bevacizumab, Other Drugs
2) By End User: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other End-Users
Subsegments:
1) By Temozolomide: Oral Formulation, Injectable Formulation
2) By Bevacizumab: Monoclonal Antibody Therapy, Combination Therapy With Chemotherapy
3) By Other Drugs: Carmustine, Lomustine, Etoposide, Irinotecan, Novantrone (Mitoxantrone)

Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Who are the most influential companies in the brain tumor drugs market?
Major companies operating in the brain tumor drugs market include  F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co., Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratórios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

What are the most influential trends expected to drive the brain tumor drugs market forward?
Companies in the brain tumor drugs market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a reduction in the dosage of the drugs, improved shelf life, and reduced toxicity. A few nano drugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of Brain tumors. For instance, Liposomes nanoparticles facilitate easy delivery of drugs to the core cancer cells, these particles if coated with transferrin can even pass through the blood-brain barrier. Companies including GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are adopting this technology to improve the available techniques of medication and treatment.

What are the major regional insights for the brain tumor drugs market, and which region holds the top position?
The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

What Does The Brain Tumor Drugs Market Report 2025 Offer?
The brain tumor drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Brain tumor drugs refer to the drugs or medications that are used to treat brain tumors. Chemotherapy, hormone therapies, anticonvulsants, and painkillers are among the drugs used to treat brain tumors. While other prescription drugs are used to manage symptoms while the tumor is being treated, chemotherapy works to reduce or destroy brain tumors.

Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2588

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model